Unknown

Dataset Information

0

Surfactant-Free Chitosan/Cellulose Acetate Phthalate Nanoparticles: An Attempt to Solve the Needs of Captopril Administration in Paediatrics.


ABSTRACT: The Paediatric Committee of the European Medicines Agency encourages research into medicinal products for children, in particular, the development of an age-appropriate formulation of captopril is required in the cardiovascular therapeutic area. The aim of this study was the development of a liquid formulation using nanoparticles based only on chitosan and cellulose acetate phthalate containing captopril for the treatment of hypertension, heart failure and diabetic nephropathy in paediatric patients. Nanoparticles were prepared by a nanoprecipitation method/dropping technique without using surfactants, whose use can be associated with toxicity. A range of different cellulose to chitosan weight ratios were tested. A good encapsulation efficiency (61.0 ± 6.5%) was obtained when a high chitosan concentration was used (1:3 ratio); these nanoparticles (named NP-C) were spherical with a mean diameter of 427.1 ± 32.7 nm, 0.17 ± 0.09 PDI and +53.30 ± 0.95 mV zeta potential. NP-C dispersion remained stable for 28 days in terms of size and drug content and no captopril degradation was observed. NP-C dispersion released 70% of captopril after 2 h in pH 7.4 phosphate buffer and NP-C dispersion did not have a cytotoxicity effect on neonatal human fibroblasts except at the highest dose tested after 48 h. As a result, chitosan/cellulose nanoparticles could be considered a suitable platform for captopril delivery in paediatrics for preparing solid/liquid dosage forms.

SUBMITTER: Nieto Gonzalez N 

PROVIDER: S-EPMC9228859 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Surfactant-Free Chitosan/Cellulose Acetate Phthalate Nanoparticles: An Attempt to Solve the Needs of Captopril Administration in Paediatrics.

Nieto González Noelia N   Cerri Guido G   Molpeceres Jesús J   Cossu Massimo M   Rassu Giovanna G   Giunchedi Paolo P   Gavini Elisabetta E  

Pharmaceuticals (Basel, Switzerland) 20220525 6


The Paediatric Committee of the European Medicines Agency encourages research into medicinal products for children, in particular, the development of an age-appropriate formulation of captopril is required in the cardiovascular therapeutic area. The aim of this study was the development of a liquid formulation using nanoparticles based only on chitosan and cellulose acetate phthalate containing captopril for the treatment of hypertension, heart failure and diabetic nephropathy in paediatric pati  ...[more]

Similar Datasets

| S-EPMC6239201 | biostudies-literature
| S-EPMC5605889 | biostudies-literature
| S-EPMC113252 | biostudies-literature
| S-EPMC57811 | biostudies-literature
| S-EPMC6102242 | biostudies-literature
| S-EPMC8355739 | biostudies-literature
| S-EPMC11697331 | biostudies-literature
| S-EPMC8766282 | biostudies-literature
| S-EPMC10052346 | biostudies-literature
| S-EPMC10346856 | biostudies-literature